Comparison of Lanreotide AutogelÂ® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.
Malignant Carcinoid Syndrome
DRUG: lanreotide Autogel (somatostatin analogue)|DRUG: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Target symptom frequency (flushing or stool frequency).
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with carcinoid syndrome.